Get the latest tech news
Allozymes puts its accelerated enzymatics to work on a data and AI play, raising $15M
Allozymes uses a method in which millions of enzymes can be tested per day, rather than just a few hundred.
Finding a cheap and effective one is seldom easy, and until recently the entire industry was testing about a million possibilities per year — a number Allozymes aims to multiply over a thousandfold, targeting 7 billion variants in 2024. The idea is hardly unprecedented: We’ve covered numerous companies and research projects that have found machine learning models can be very helpful in sorting through huge datasets, offering extra confidence even if their outcomes can’t be substituted for the real process. The $15 million A round includes new investors Seventure Partners, NUS Technology Holdings, Thia Ventures, and ID Capital, with repeat investment from Xora Innovation, SOSV, Entrepreneur First and Transpose Platform.
Or read this on TechCrunch